Tools for Practice

#225 Topical Capsaicin for Neuropathic and Osteoarthritis Pain: Maybe not so hot?

What are the benefits and harms of topical capsaicin for neuropathic or osteoarthritis pain?

Evidence for topical capsaicin in neuropathic pain and hand osteoarthritis is highly inconsistent, with some studies showing clinical benefit (variably defined) for one in 4-7 patients while other studies show no benefit. There is no benefit in knee osteoarthritis. Local adverse effects (burning, stinging) in up to 60% of patients lead to one in 8-9 more stopping therapy.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

Join Now

Already a CFPCLearn Member? Log in

Neuropathic pain: 
  • Systematic review [seven Randomized Controlled Trials (RCTs), 1,600 patients, varied neuropathic pain types], 0.075% topical capsaicin versus placebo, 6-12 weeks:1 
    • Clinical improvement (variably defined): 42% versus 28% (placebo), not statistically different. 
    • Adverse events: 
      • Burning, stinging, or erythema: 63% versus 24% (placebo), Number Needed to Harm (NNH)=3. 
      • Coughing, sneezing: 9% versus 1% (placebo)NNH=13. 
      • Withdrawal: 15% versus 3% (placebo), NNH=9. 
  • Two other systematic reviews, 0.075% capsaicin versus placebo, at 4-8 weeks:2,3 
    • Benefit:  
      • Physician-rated “Much Better” (four RCTs, 309 patients):2 73% versus 49%, Number Needed to Treat (NNT)=5. 
      • ≥50% pain improvement (10 RCTs, 969 patients):3 NNT~7. 
    • Adverse events:3 
      • Local reaction: 58% versus 18%, NNH=3. 
      • Withdrawal: 16% versus 2%, NNH=8. 
  • RCT of 33 diabetic neuropathy patients,4 0.025% gel versus placebo: 
    • Pain score or patients achieving 30% pain reduction: No difference. 
    • Adverse skin reaction: 15% versus 0% (placebo), NNH=6. 
Osteoarthritis pain:  
  • Two systematic reviews (3-4 RCTs, 301-382 patients, hand osteoarthritis), 0.025%-0.075% topical capsaicin versus placebo at 4-8 weeks:2,5 
    • Clinical improvement, variably defined:2 45% versus 16%, NNT=4. 
    • Pain score ~8/100 points lower than placebo.5  
    • Adverse events not reported.2   
  • RCT (99 patients, knee osteoarthritis), 0.0125% capsaicin versus placebo over four weeks:6 No improvement. 
Limitations: Blinding likely compromised due to burning and redness.  Context: 
  • Burning or stinging usually receeds after several days of use.7 
  • 60-gram tube of 0.075% Capsaicin cream costs ~$30 (about 60-day supply based on QID use, depending on area). 
  • NICE recommends for localized neuropathic pain when oral medications not tolerated8 and as an add-on therapy for knee or hand osteoarthritis pain.9  

Latest Tools for Practice

#341 Forget about it? Statins and the risk of dementia (Free)

Do statins negatively affect cognition, memory, or dementia?
Read 0.25 credits available

#340 Crying babies: Can proton pump inhibitors help? (Free)

In infants (≤1year) with crying/irritability attributed to feeds, do proton pump inhibitors (PPIs) improve symptoms over placebo without additional harms?
Read 0.25 credits available

#339 Is acetaminophen under pressure?

Does regular use of acetaminophen increase blood pressure?
Read 0.25 credits available

This content is certified for MainPro+ Credits, log in to access


  • Danielle Perry BScN RN
  • G. Michael Allan MD CCFP

1. Derry S, Moore RA. Cochrane Database Syst Rev. 2012; (9):CD010111.

2. Zhang WY, Li Wan Po A. Eur J Clin Pharmacol. 1994; 46(6):517-22.

3. Mason L, Moore RA, Derry S, et al. BMJ. 2004; 328(7446):991.

4. Kulkantrakorn K, Lorsuwansiri C, Meesawatsom P. Pain Pract. 2013; (6):497-503.

5. Cameron M, Gagnier JJ, Little CV, et al. Phytother Res. 2009;(11):1497-515.

6. Cameron M, Chrubasik S. Cochrane Database Syst Rev. 2013; (5):CD010538.

7. CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2018 [updated 2018 July]. Capsaicin [product monograph] Available from: or Last Accessed: July 7, 2018.

8. National Institute for Health and Care Excellence. NICE Guideline (CG173). Available from: Last Accessed: June 27, 2018.

9. National Institute for Health and Care Excellence. NICE Guideline (CG177). Available from: Last Accessed: July 9, 2018.

Authors do not have any conflicts of interest to declare.